

PATENT APPLICATION  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q87757

Toshiyuki TAKASU, et al.

Appln. No.: National Stage Entry of PCT/JP03/14065

Confirmation No.: Unknown

Group Art Unit: Unknown

Filed: May 09, 2005

Examiner: Unknown

For: REMEDY FOR OVERACTIVE BLADDER COMPRISING ACETIC ACID ANILIDE  
DERIVATIVE AS THE ACTIVE INGREDIENT

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 C.F.R. §§ 1.97 and 1.98**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following:

1. Copies of U.S. patents and/or U.S. patent publications are not provided; and copies of co-pending non-provisional U.S. applications filed after June 30, 2003 are not provided.
2. In the case of the GB document and certain of the WO documents, the cover page only is provided, together with a citation to a corresponding U.S. Patent, U.S. Patent Publication, or EP Publication.

INFORMATION DISCLOSURE STATEMENT  
National Stage Entry of PCT/JP03/14065

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for foreign language documents, Applicant encloses herewith a copy of a Communication from a foreign patent office in a counterpart application citing such documents, together with an English-language version (if not already included) of at least that portion of the Communication indicating the degree of relevance found by the foreign patent office.

Additionally, U.S. 6,291,491 B1 corresponds to GB 2,356 197 A; U.S. 6,346,532 B1, corresponds to WO 99/20607 A1; U.S. 2003/073846 A1 corresponds to WO 01/062705 A2; U.S. 6,538,152 B1 corresponds to WO 00/002846 A1; EP 0 958 835 corresponds to WO 98/07445; and US 6,696,489 and US 6,790,865 correspond to WO 99/52856. WO 98/07445, WO 99/52856 and WO 99/31045 are cited and discussed in the specification.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

INFORMATION DISCLOSURE STATEMENT  
National Stage Entry of PCT/JP03/14065

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.


SUGHRUE MION, PLLC  
Telephone: (202) 293-7060  
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Respectfully submitted,

  
For Mark Boland  
Registration No. 32,197

Date: May 9, 2005

Substitute for Form 1449 A & B/PTO  <b><u>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</u></b>  <i>(use as many sheets as necessary)</i>				Complete if Known 10/534290		
				Application Number Confirmation Number Filing Date First Named Inventor Art Unit Examiner Name Attorney Docket Number		National Stage Entry of PCT/JP03/14065  May 09, 2005 Toshiyuki TAKASU      Q87757
Sheet	1	of	1			

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code <sup>2</sup> (if known)		
		US 6,291,491	B1	09-18-2001	Ann E. Weber, et al.
		US 6,346,532	B1	02-12-2002	Tatsuya Maruyama, et al.
		US 2003/0073846	A1	04-17-2003	Kiyoshi Taniguchi, et al.
		US 6,538,152	B1	03-25-2003	Nobuyuki Tanaka, et al.
		US 6,353,025	B1	03-05-2002	Tetsuro Tamai, et al.
		US 6,696,489	B1	02-24-2004	Tetsuro Tamai, et al.
		US 6,790,865	B2	09-14-2004	Tetsuro Tamai, et al.

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Translation <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
		GB	2 356 197	A	05-16-2001	MERCK & CO INC	Abstract
		WO	99/20607	A1	04-29-1999	YAMANOUCHI PHARMACEUTICAL CO., LTD.	Abstract
		WO	02/00622	A2	01-03-2002	FUJI-SAWA PHARMACEUTICAL CO., LTD.	Abstract
		WO	01/62705	A2	08-30-2001	FUJI-SAWA PHARMACEUTICAL CO., LTD.	Abstract
		JP	2001-114736	A	04-24-2001	KISSEI YAKUHHN KOGYO KK	Abstract
		WO	00/02846	A1	01-20-2000	KISSEI PHARMACEUTICAL CO., LTD.	Abstract
		WO	98/07445	A1	02-26-1998	KISSEI PHARMACEUTICAL CO., LTD.	Abstract
		EP	0 958 835	A1	11-24-1999	KISSEI PHARMACEUTICAL CO., LTD.	
		WO	99/31045	A1	06-24-1999	KISSEI PHARMACEUTICAL CO., LTD.	Abstract
		WO	99/52856	A1	10-21-1999	KISSEI PHARMACEUTICAL CO., LTD.	Abstract

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation <sup>6</sup>
		Ralph HOWE, "β-ADRENERGIC AGONISTS", Drugs of the Future, 1993, Volume 18, No. 6, pages 529-549	
		Nathalie BLIN, et al., "STRUCTURAL AND CONFORMATIONAL FEATURES DETERMINING SELECTIVE SIGNAL TRANSDUCTION IN THE β3-ADRENERGIC RECEPTOR", The American Society for Pharmacology and Experimental Therapeutics, 1993, Volume 44, Pages 1094-1104	
		Takashi MORITA, et al., The Japanese Journal of Urology, 88 (2), Page 119, (page 183) 1997	YES
		Yasuhiko IGAWA, et al., The Japanese Journal of Urology, 88 (2), Page 119, (page 183) 1997	YES

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to indicate here if English language Translation is attached.